<p>A) Platelet expression of C4d was analyzed in 148 SLE patients and grouped into patients with or without anti-phospholipid (aPL) or anti-cardiolipin (aCL) antibodies at the time of blood sampling. The line represents the median value in each group. B) Platelet expression of CD69 was measured by flow cytometry in healthy volunteers (HV), patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc) and myocardial infarction (MI). The line represents the median value in each group. C) Correlation analysis between C1q deposition on platelets and platelet activation marker CD69 in the 148 SLE patients.</p
To evaluate the association between lupus severity and cell-bound complement activation products (CB...
Background: We examined the usefulness of erythrocyte-bound C4d (EC4d) to monitor disease activity i...
OBJECTIVE: To evaluate the frequency of cell-bound complement activation products (CB-CAPs) as a mar...
Anti-phospholipid (aPL) antibodies are important contributors to development of thrombosis in patien...
OBJECTIVE: Complement components, including C4d, can be found on activated platelets, a process asso...
Anti-phospholipid (aPL) antibodies are important contributors to development of thrombosis in patien...
<p>C4d deposition on platelets from SLE patients was correlated to A) serum level of C3, B) serum le...
Objective: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing vas...
Premature, accelerated onset of atherothrombotic disease is prevalent in patients with systemic lupu...
Complement plays a major role in inflammation and thrombosis associated with systemic lupus erythema...
APS is the association of antiphospholipid antibodies (aPL) with thromboses and/or recurrent pregnan...
Antiphospholipid syndrome (APS) is a chronic and disabling condition characterized by recurrent thro...
Background Systemic lupus erythematosus (SLE) is a complex disease characterized by autoimmunity tow...
10.1016/j.atherosclerosis.2012.08.029Background The complement system is involved in the pathogenic ...
This study was conducted to (1) characterize coagulation cascade and complement system in systemic l...
To evaluate the association between lupus severity and cell-bound complement activation products (CB...
Background: We examined the usefulness of erythrocyte-bound C4d (EC4d) to monitor disease activity i...
OBJECTIVE: To evaluate the frequency of cell-bound complement activation products (CB-CAPs) as a mar...
Anti-phospholipid (aPL) antibodies are important contributors to development of thrombosis in patien...
OBJECTIVE: Complement components, including C4d, can be found on activated platelets, a process asso...
Anti-phospholipid (aPL) antibodies are important contributors to development of thrombosis in patien...
<p>C4d deposition on platelets from SLE patients was correlated to A) serum level of C3, B) serum le...
Objective: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing vas...
Premature, accelerated onset of atherothrombotic disease is prevalent in patients with systemic lupu...
Complement plays a major role in inflammation and thrombosis associated with systemic lupus erythema...
APS is the association of antiphospholipid antibodies (aPL) with thromboses and/or recurrent pregnan...
Antiphospholipid syndrome (APS) is a chronic and disabling condition characterized by recurrent thro...
Background Systemic lupus erythematosus (SLE) is a complex disease characterized by autoimmunity tow...
10.1016/j.atherosclerosis.2012.08.029Background The complement system is involved in the pathogenic ...
This study was conducted to (1) characterize coagulation cascade and complement system in systemic l...
To evaluate the association between lupus severity and cell-bound complement activation products (CB...
Background: We examined the usefulness of erythrocyte-bound C4d (EC4d) to monitor disease activity i...
OBJECTIVE: To evaluate the frequency of cell-bound complement activation products (CB-CAPs) as a mar...